NEOIMMUNETECH, INC

44 articles with NEOIMMUNETECH, INC

• NeoImmuneTech Announces Initiation of Clinical Trial for HyLeukin-7 Treatment in Combination with Standard Therapy for Newly Diagnosed Brain Cancer Patients

  10/29/2018

  HyLeukin-7 is an immunotherapeutic drug candidate designed to induce T cell proliferation and help the body fight serious disease.

• NeoImmuneTech Strengthens Senior Management with the Appointment of NgocDiep Le, M.D., Ph.D., as Chief Medical Officer

  10/29/2018

  NeoImmuneTech, Inc., an immunotherapy drug development company focused on advanced cancer treatments, today announced the appointment of NgocDiep (‘Diep’) Le, M.D., Ph.D., as Chief Medical Officer (CMO)

• NeoImmuneTech Announces Initiation of HyLeukin-7 Clinical Development for Cancer Patients in the U.S.

  5/29/2018

  ​NeoImmuneTech, Inc. announced today the initiation of its first U.S. clinical trial.

• NeoImmuneTech Announces a Clinical Trial Collaboration with a Global Leading Pharmaceutical Company to Evaluate HyLeukin-7 in Combination with a PD-L1 Checkpoint Inhibitor in Advanced High-Risk Skin Cancers

  5/1/2018

  NeoImmuneTech have entered into an agreement with Roche to enable studies of a combination treatment in three advanced high-risk skin cancer types.